Lunsumio 1 Mg/1 Ml & 30 Mg/ 30 Ml 1 mg, 30 mg Concentrate for solution for intravenous Infusion
PDF Leaflet Revision Date: 18 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Dosage (summary)
Cycle 1: Day 1 - 1 mg, Day 8 - 2 mg, Day 15 - 60 mg; Cycle 2: Day 1 - 60 mg; Cycle 3+: Day 1 - 30 mg.
Special Populations
- Geriatric patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid during pregnancy unless benefits outweigh risks; discontinue breastfeeding during therapy.
Key Drug Interactions
- CYP3A substrates
Contraindications
- Hypersensitivity to mosunetuzumab or excipients
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Diarrhea
- Pyrexia
- Cytokine release syndrome
Counselling Points
- Premedicate with corticosteroids, antihistamines, and antipyretics
- Monitor for signs of CRS
- Seek immediate medical attention for CRS symptoms
Serious warnings
- Cytokine release syndrome
- Serious infections
- Tumor flare
- Tumor lysis syndrome
Important Disclaimer
The Lunsumio 1 Mg/1 Ml & 30 Mg/ 30 Ml 1 mg, 30 mg Concentrate for solution for intravenous Infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
